West Virginia Reaches Settlement with Juul Labs Inc.

Apr.11.2023
West Virginia Reaches Settlement with Juul Labs Inc.
West Virginia settles lawsuit with Juul for $7.9 million over allegations of unfair or fraudulent practices targeting minors.

The state of West Virginia has reached a settlement with e-cigarette manufacturer Juul Labs Inc. (hereafter referred to as Juul) over allegations that the company violated the state's consumer credit and protection laws.


Electronic cigarette manufacturer Juul has agreed to pay a $7.9 million settlement to the state. The company has been accused of engaging in unfair or deceptive practices, particularly targeted towards minors, in the manufacturing, design, sales, marketing, promotion, and distribution of e-cigarettes within the state. According to State Attorney General Patrick Morrisey, the settlement will prevent companies like Juul from adopting marketing strategies that target minors. Morrisey stated that the company was accused of deceiving consumers about the nicotine content, misrepresenting the nicotine equivalency between their products and traditional cigarettes, and underestimating the addictive risks associated with their high nicotine levels.


According to a statement from Austin Finan, Vice President of Corporate Communications for Juul Labs, this settlement represents "another step in Juul Labs' ongoing commitment to address the company's past issues.


According to Finan, the terms of the settlement agreement are similar to previous settlements and provide financial resources for further efforts to combat underage smoking and develop smoking cessation programs. This reflects the current business practices that have been implemented since the company's comprehensive relaunch in the fall of 2019. Given that West Virginia has the highest smoking rate in the United States, the company hopes that some of the funds will be directly used to reduce smoking and improve public health within the state.


According to Finan, Juul has reached a settlement with "40 states and regions, providing billions of dollars for participating states." As reported by 2FIRSTS before, Juul has already paid over $2.6 billion in settlements to different states. Finan stated, "This settlement is based on us resolving private lawsuits across the country and covers over 5,000 cases brought by approximately 10,000 plaintiffs.


According to data from the US Centers for Disease Control and Prevention (CDC), Juul e-cigarettes contain high levels of nicotine - the amount of nicotine in one Juulpod is equivalent to 20 regular cigarettes. However, the defense disagrees with this data, arguing that the total amount of nicotine in Juulpods is "equivalent to 1.72 packs (34 cigarettes).


The amount of nicotine contained in one Juulpod is equivalent to at least 20 regular cigarettes, according to a photo source provided by the Associated Press.


In 2017, 14.3% of high school students in West Virginia reported using e-cigarettes for at least one day in the past 30 days. This figure was slightly higher than the national average of 13.2%.


According to data from the 2019 National Youth Tobacco Survey, over 5 million American middle and high school students are currently using e-cigarettes, with 27.5% of high schoolers and 10.5% of middle schoolers reporting current use. Among these current e-cigarette users, 34.2% of high schoolers and 18% of middle schoolers use e-cigarettes for 20 or more days each month.


Related Reading:


2FIRSTS special: Juul settlement summary


JUUL has spent $18.2 billion in hopes of reaching a settlement. Here is a breakdown of the settlement amounts and conditions in each state.


Juul has reached a $24 million settlement agreement with Chicago.


A US district court has approved a $255m class-action settlement with Juul prior to trial.


E-cigarette company JUUL has paid a total of $1.7 billion in settlements after 34 states filed lawsuits against the company.


References:


The state of West Virginia has come to an agreement with e-cigarette company Juul.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JTI Research Finds 31% of UK Respondents Offered Illicit Tobacco, While 63% of Ennis Packs Lack Duty Marks
JTI Research Finds 31% of UK Respondents Offered Illicit Tobacco, While 63% of Ennis Packs Lack Duty Marks
Multiple JTI-backed studies in the UK and Ireland indicate that illicit tobacco remains visible across consumer interactions and local markets. In the UK, JTI research found that 31% of respondents said they had been offered illicit tobacco products. In Ireland’s Ennis area, a JTI-commissioned empty pack survey found that 63% of sampled cigarette packs did not carry Irish duty-paid markings. The findings come from industry research rather than official government estimates of illicit tobacco market size, but highlight continued concerns among regulators, legitimate retailers and tobacco companies over illicit trade.
Aug.19
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Mesa Underwriters Specialty Insurance Company has asked a federal court in Washington to declare that it has no duty to defend or indemnify vape distributor i5 Distribution in a product liability case involving an Elf Bar BC5000. The plaintiff alleges that the disposable vape caught fire and exploded in his pocket, causing severe burns and ultimately requiring an above-the-knee amputation of his left leg. MUSIC is relying on a tobacco, nicotine or nicotine replacement products exclusion and a premises limitation endorsement. The court has not ruled on the coverage dispute.
News
Sep.10
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives